ANI PHARMACEUTICALS, INC Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted
ANI PHARMACEUTICALS, INC (ANIP) reported Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted of $1.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Earnings Per Share › Undistributed Earnings (Loss) Available to Common Shareholders, Diluted
us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted · last filed 2026-08-07
- ANI PHARMACEUTICALS, INC undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2026-06-30 was $1.66M, a 106.48% increase year-over-year.
- ANI PHARMACEUTICALS, INC undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2026-03-31 was $2.01M, a 30.92% increase year-over-year.
- ANI PHARMACEUTICALS, INC undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2025-12-31 was $1.98M.
- ANI PHARMACEUTICALS, INC undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2025-09-30 was $2.37M.
- ANI PHARMACEUTICALS, INC undistributed earnings (loss) allocated to participating securities, diluted for fiscal 2025 was $6.61M.
- ANI PHARMACEUTICALS, INC undistributed earnings (loss) allocated to participating securities, diluted for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ANI PHARMACEUTICALS, INC undistributed earnings (loss) allocated to participating securities, diluted for fiscal 2023 was $1.66M.
- ANI PHARMACEUTICALS, INC undistributed earnings (loss) allocated to participating securities, diluted for fiscal 2022 was $0.00.
| Period end | Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted 3 month | Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted 3 month as first filed | Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted 6 month | Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted 9 month | Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.66M 10-Q · filed 2026-08-07 | $3.65M 10-Q · filed 2026-08-07 | $5.64M derived: sum of 3 quarters · filed 2026-08-07 | $8.01M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | $2.01M 10-Q · filed 2026-05-08 | $3.98M derived: sum of 2 quarters · filed 2026-05-08 | $6.36M derived: sum of 3 quarters · filed 2026-05-08 | $7.16M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $4.35M derived: sum of 2 quarters · filed 2026-02-27 | $5.15M derived: sum of 3 quarters · filed 2026-08-07 | $6.61M 10-K · filed 2026-02-27 | |
| 2025-09-30 | $2.37M 10-Q · filed 2025-11-07 | $3.18M derived: sum of 2 quarters · filed 2026-08-07 | $4.63M 10-Q · filed 2025-11-07 | $4.71M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | $802.00K 10-Q · filed 2026-08-07 | $2.32M 10-Q · filed 2026-08-07 | $2.33M derived: sum of 3 quarters · filed 2026-08-07 | $2.33M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-03-31 | $1.53M 10-Q · filed 2026-05-08 | $1.53M derived: sum of 2 quarters · filed 2026-05-08 | $1.53M derived: sum of 3 quarters · filed 2026-05-08 | $1.53M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | $1.83M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-08 | $1.47M 10-Q · filed 2025-08-08 | $1.83M derived: sum of 3 quarters · filed 2026-02-27 | $2.71M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-03-31 | $1.78M 10-Q · filed 2025-05-09 | $1.83M derived: sum of 2 quarters · filed 2026-02-27 | $2.71M derived: sum of 3 quarters · filed 2026-02-27 | $3.30M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2023-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $929.00K derived: sum of 2 quarters · filed 2026-02-27 | $1.52M derived: sum of 3 quarters · filed 2026-02-27 | $1.66M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $881.00K 10-Q · filed 2024-11-08 | $1.47M derived: sum of 2 quarters · filed 2024-11-08 | $1.61M 10-Q · filed 2024-11-08 | $1.58M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-06-30 | $589.00K 10-Q · filed 2024-08-06 | $716.00K 10-Q · filed 2024-08-06 | $702.00K derived: sum of 3 quarters · filed 2025-02-28 | $702.00K derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-03-31 | $113.00K 10-Q · filed 2024-05-10 | $113.00K derived: sum of 2 quarters · filed 2025-02-28 | $113.00K derived: sum of 3 quarters · filed 2025-02-28 | $113.00K derived: sum of 4 quarters · filed 2025-02-28 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 derived: sum of 3 quarters · filed 2025-02-28 | $0.00 10-K · filed 2025-02-28 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 | ||||
| 2021-03-31 | $5.00K 10-Q · filed 2022-05-10 | -$5.00K 10-Q · filed 2021-05-07 | |||
| 2020-09-30 | -$13.00K 10-Q · filed 2021-11-01 | ||||
| 2020-06-30 | -$19.35M 10-Q · filed 2020-08-06 | ||||
| 2019-12-31 | $79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $16.00K derived: sum of 2 quarters · filed 2021-03-11 | -$97.00K 10-K · filed 2021-03-11 | ||
| 2019-09-30 | -$63.00K 10-Q · filed 2020-11-05 | -$176.00K 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $6.92M 10-Q · filed 2020-08-06 | ||||
| 2018-12-31 | -$154.00K 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |